Evoke Pharma (EVOK) Company Report

Evoke Pharma, Inc. was acquired by QOL Medical, LLC through a tender offer and subsequent merger.
Evoke stockholders received $11.00 per share in cash.
The tender offer expired on December 15, 2025, with approximately 67.63% of outstanding shares tendered.
As a result of the merger, Evoke became a wholly owned subsidiary of QOL Medical, and its shares ceased trading on Nasdaq on December 17, 2025, with plans for delisting and deregistration.

Dec 17, 2025, 3:50 PM

Monteverde & Associates PC Launches Legal Inquiry for Evoke Pharma Sale

EVOK

M&A

Legal Proceedings

Monteverde & Associates PC has launched a legal inquiry into the sale of Evoke Pharma, Inc. (NASDAQ:EVOK) to QOL Medical, LLC.
Under the terms of the proposed transaction, Evoke shareholders are expected to receive $11.00 per share in cash.
The tender offer for this transaction is set to expire on December 15, 2025.

Nov 18, 2025, 1:30 AM

Evoke Pharma's Sale to QOL Medical Faces Legal Inquiry

EVOK

M&A

Legal Proceedings

Takeover Bid

Evoke Pharma, Inc. (NASDAQ:EVOK) is undergoing a legal inquiry by Monteverde & Associates PC concerning its proposed sale to QOL Medical, LLC.
Shareholders of Evoke Pharma are expected to receive $11.00 per share in cash as part of the transaction.

Nov 13, 2025, 10:30 PM

Evoke Pharma Reports Q3 2025 Results and Announces Acquisition by QOL Medical

EVOK

Earnings

M&A

Revenue Acceleration/Inflection

Evoke Pharma announced an agreement on November 4, 2025, to be acquired by QOL Medical for $11.00 per share in cash, with the transaction expected to close in the fourth quarter of 2025.
For the third quarter of 2025, net product sales reached $4.3 million, representing a 61% increase year-over-year, and year-to-date sales totaled $11.1 million, a 60% increase compared to the same period in 2024.
The company reported a net loss of approximately $1.2 million, or ($0.45) per share, for the third quarter of 2025.
A new U.S. patent for GIMOTI (U.S. Patent No. 12,377,064) was received in August 2025, extending its expected exclusivity to November 2038.
As of September 30, 2025, Evoke had $11.6 million in cash and cash equivalents, which is projected to fund operations into the fourth quarter of 2026.

Nov 13, 2025, 12:05 PM

Evoke Pharma to Be Acquired by QOL Medical

EVOK

M&A

Takeover Bid

Evoke Pharma, Inc. has entered into a definitive agreement to be acquired by QOL Medical, LLC.
QOL Medical will acquire all outstanding shares of Evoke for $11.00 per share in cash.
This purchase price represents a 139.7% premium to Evoke’s closing share price on November 3, 2025.
The transaction is expected to close by the end of 2025 and will result in Evoke ceasing to be a publicly traded company.

Nov 4, 2025, 12:12 PM

Evoke Pharma to be Acquired by QOL Medical

EVOK

M&A

Takeover Bid

QOL Medical, LLC will acquire all outstanding shares of Evoke Pharma, Inc. for $11.00 per share in cash.
This purchase price represents a 139.7% premium to Evoke’s closing share price on November 3, 2025.
The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close by the end of 2025.
The acquisition highlights the strategic value of Evoke's commercial product, GIMOTI® (metoclopramide) nasal spray, which is the first and only FDA-approved nasal spray for acute and recurrent diabetic gastroparesis in adults.